From Yahoo Finance: 2025-04-12 18:45:00

Last week, 10 firms defied the market slump with double-digit gains. Summit Therapeutics Inc. (SMMT) surged by 33.87%, ending at $23.24. Positive ratings from Cantor Fitzgerald and Truist Securities, along with co-CEO Bob Duggan’s share acquisition, boosted investor confidence. SMMT focuses on biopharmaceutical oncology, ranking 3rd on the list.

Despite market uncertainties, Nasdaq led with a 7.29% gain, followed by S&P 500 at 5.7% and Dow Jones at 4.95%. Investors sought refuge in gold and biopharmaceutical sectors, driving ten companies to record high gains. Our list identified these top performers and analyzed their success factors.

To compile the list, we considered only stocks with a $2 billion market cap and $5 million trading volume. Week-on-week prices were based on closing prices on Friday compared to a week prior. Summit Therapeutics Inc. stood out with a 33.87% surge, closing at $23.24 last week. Positive ratings and share acquisition by co-CEO Bob Duggan drove investor optimism.

Cantor Fitzgerald maintained an Overweight rating on SMMT, while Truist Securities issued a Buy rating with a $35 price target. SMMT, a biopharmaceutical oncology company, ranks 3rd among firms defying the market slump. While SMMT shows promise, we believe AI stocks hold greater potential for higher returns in a shorter timeframe. For a promising, undervalued AI stock, check out our report on the cheapest AI stock currently available.

Read more: Why Summit Therapeutics Inc. (SMMT) Soared Last Week?